Dr Steve Patterson joined Prof Frances Gotch’s Immunology Department at Chelsea & Westminster Hospital in 1999. The groups focus is on the role of dendritic cells (DCs) in HIV pathogenesis and research to progress the development of a HIV vaccine.
Currently, the group comprises 2 post doctoral scientists, 3 PhD students and a Project Manager. Its current research efforts are focussed predominantly in the area of DC biology and HIV vaccine development. The group benefits from the diverse expertise of its members, both at post-doctoral and at PhD student level, which covers research areas such as immunology (ex vivo analysis, flow cytometry), molecular biology, (vector construction and development), virology (production of Adenovirus).
The group’s recent work has shown that in HIV-infected patients there is a progressive loss of blood myeloid and plasmacytoid DCs. The former are the precursors of tissue Langerhans cells and interstitial DCs and the latter are precursors of cells that are the main producers of interferon alpha. Both DC populations were shown to be susceptible to HIV infection in vitro. Recent studies in which the two DC populations have been purified from the blood of HIV-infected patients have shown that HIV infection is associated with impaired T cell stimulatory capacity by both types of DC and current work aims to elucidate the underlying mechanisms involved.
The group benefits from an active collaboration with a large routine diagnostic immunology laboratory that services the largest HIV clinic in Europe. The academic department is also well equipped for molecular biology, cellular immunology and HIV work. The London International AIDS Vaccine Initiative (IAVI) Core Laboratory is an integral part of the department.
Recent publications include:
"CD34-derived human Langerhans cells stimulate a T helper type 2 response independently of extracellular-signal-regulated kinase phosphorylation." Immunology May 2010 Epub ahead of print . Duraisingham SS et al.
"Adenovirus vector vaccination induces expanision of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1." Proc Natl Acad Sci USA. 2009 Nov 24;106(47):19940-5. Benlahrech A et al.
"TLR-stimulated CD34 stem cell-derived human skin-like and monocyte-derived dendritic cells fail to induce Th17 polarization of naive T cells but do stimulate Th1 and Th17 memory responses." J Immunol. 2009 Aug 15;183(4):2242-51. Duraisingham SS et al.
"Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10." J Infect Dis. 2009 Jun 15;199(12):1862-71. Buisson S et al.
"Use of adenovirus in vaccines for HIV." Handb Exp Pharmacol. 2009;(188):275-93. Patterson S et al.
Dr Patterson is in receipt of a $9.2 million grant awarded by the Collaboration for AIDS Vaccine Development (CAVD), funded in part by the Bill and Melinda Gates foundation. The Patterson Vaccine Discovery Consortium's project aims to develop a HIV CD8+ T cell vaccine targeted to Dendritic cells in the skin that will induce a broad CTL repsonse. The 5 year award was given in July 2006.
See "HIV Vaccine Development Development" page for further details.